Related Experiment Video
Updated: Apr 27, 2026
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Mapping lymph nodes in cancer management - role of (99m)Tc-tilmanocept injection
Christoph Tausch1, Astrid Baege1, Christoph Rageth1
1Brust-Zentrum, Zürich, Switzerland.
Abstract:
Two decades ago, lymphatic mapping of sentinel lymph nodes (SLN) was introduced into surgical cancer management and was termed sentinel node navigated surgery. Although this technique is now routinely performed in the management of breast cancer and malignant melanoma, it is still under investigation for use in other cancers. The radioisotope technetium ((99m)Tc) and vital blue dyes are among the most widely used enhancers for SLN mapping, although near-infrared fluorescence imaging of indocyanine green is also becoming more commonly used. (99m)Tc-tilmanocept is a new synthetic radioisotope with a relatively small molecular size that was specifically developed for lymphatic mapping. Because of its small size, (99m)Tc-tilmanocept quickly migrates from its site of injection and rapidly accumulates in the SLN. The mannose moieties of (99m)Tc-tilmanosept facilitate its binding to mannose receptors (CD206) expressed in reticuloendothelial cells of the SLN. This binding prevents transit to second-echelon lymph nodes. In Phase III trials of breast cancer and malignant melanoma, and Phase II trials of other malignancies, (99m)Tc-tilmanocept had superior identification rates and sensitivity compared with blue dye. Trials comparing (99m)Tc-tilmanocept with other (99m)Tc-based agents are required before it can be routinely used in clinical settings.
Insights
Sentinel lymph node (SLN) mapping uses new agents like (99m)Tc-tilmanocept for improved cancer detection. This technique shows promise in identifying cancer spread, especially in breast cancer and melanoma.
Area of Science:
- Oncology
- Surgical Oncology
- Nuclear Medicine
Background:
- Sentinel lymph node (SLN) mapping, or sentinel node navigated surgery, has been standard in breast cancer and melanoma management for two decades.
- While widely adopted for these cancers, its application in other malignancies is still under investigation.
- Current SLN mapping commonly utilizes technetium ((99m)Tc) radioisotopes and vital blue dyes, with near-infrared fluorescence imaging gaining traction.
Purpose of the Study:
- To evaluate the efficacy of (99m)Tc-tilmanocept, a novel synthetic radioisotope, for lymphatic mapping in cancer management.
- To compare the performance of (99m)Tc-tilmanocept against traditional SLN mapping agents, particularly blue dye.
Main Methods:
- Utilized (99m)Tc-tilmanocept, a small-molecule radioisotope designed for lymphatic mapping, in Phase III trials for breast cancer and malignant melanoma, and Phase II trials for other cancers.
- Investigated the rapid migration and SLN accumulation of (99m)Tc-tilmanocept due to its small size.
- Examined the binding mechanism of (99m)Tc-tilmanocept to mannose receptors (CD206) on reticuloendothelial cells within the SLN, preventing migration to secondary lymph nodes.
Main Results:
- Phase III and II trials demonstrated superior identification rates and sensitivity for (99m)Tc-tilmanocept compared to blue dye in SLN mapping.
- (99m)Tc-tilmanocept exhibited rapid migration and accumulation in SLNs, with specific binding to mannose receptors.
Conclusions:
- (99m)Tc-tilmanocept shows significant potential as an effective agent for sentinel lymph node mapping, offering improved detection rates and sensitivity.
- Further comparative trials of (99m)Tc-tilmanocept against other technetium-based agents are necessary to establish its routine clinical utility.
